Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-03-27
2008-11-18
Kerr Bragdon, Kathleen (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S395000, C530S350000
Reexamination Certificate
active
07452859
ABSTRACT:
The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof.
REFERENCES:
patent: 5106833 (1992-04-01), Broze, Jr. et al.
patent: 5223482 (1993-06-01), Schilling, Jr. et al.
patent: 5312736 (1994-05-01), Rasmussen et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5407915 (1995-04-01), Fritz et al.
patent: 5436153 (1995-07-01), Sprecher et al.
patent: 5441931 (1995-08-01), Spreacher et al.
patent: 5541288 (1996-07-01), Nakano et al.
patent: 5576294 (1996-11-01), Norris et al.
patent: 5663143 (1997-09-01), Ley et al.
patent: 5677146 (1997-10-01), Spreacher et al.
patent: 5728674 (1998-03-01), Spreacher et al.
patent: 5731412 (1998-03-01), Shimomura et al.
patent: 5736364 (1998-04-01), Kelly et al.
patent: 5747449 (1998-05-01), Lasters et al.
patent: 5786328 (1998-07-01), Dennis et al.
patent: 5795865 (1998-08-01), Markland et al.
patent: 5834244 (1998-11-01), Dennis et al.
patent: 5854396 (1998-12-01), Shimomura et al.
patent: 6294648 (2001-09-01), Delaria et al.
patent: 0 563 389 (1993-10-01), None
patent: 0 439 442 (1996-03-01), None
patent: 0 758 682 (1997-02-01), None
patent: 92/15605 (1992-09-01), None
patent: 93/14120 (1993-07-01), None
patent: 95/18830 (1995-07-01), None
patent: 96/35788 (1996-11-01), None
patent: 96/03503 (1997-02-01), None
patent: 97/33996 (1997-09-01), None
patent: 98/33920 (1998-08-01), None
Marlor et al. (1997) Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. J. Biol. Chem. vol. 272, No. 18, pp. 12202-12208.
Jourdain et al. (1997) Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation. Am. J. Respir. Crit. Care Med. vol. 156, No. 6, pp. 1825-1833.
NCBI Sequence Viewer (bikunin [human placental bikunin] (2007, updated) http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=2065529, pp. 1-3.
NCBI Sequence Viewer (Alpha 1-microglobulin bikunin (2007, updated) http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=825614, pp. 1-2.
Inogue et al. (205) Antioxidative role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide. Int .J. Mol. Med. vol. 16, No. 16, pp. 1029-1033.
Bridges et al. (2001) Na+ transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am. J. Physiol. Lung Cell Mol. Physiol. vol. 281, No. 1, pp. L16-L23.
Delaria et al. (1997) Characterization of placental bikunin, a novel human serine protease inhibitor. J. Biol. Chem. vol. 272, No. 18, pp. 12209-12214.
Garavilla et al. (2005) A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo, J. Biol. Chem., vol. 280, No. 18, pp. 18001-18007.
Ohbayashi, H. (2002) Current synthetic inhibitors of human neutrophil elastase, Expert. Opin. Ther. Patents, vol. 12, No. 1, pp. 65-84.
App, E.M et al., “Acute and Long-term Amiloride Inhalation in Cystic Fibrosis Lung Disease”,American Review of Respiratory Disease,vol. 141, pp. 605-612, 1989.
Chraibi, A. et al, “Protease Modulation of the Activity of the Epithelial Sodium Channel Expressed inXenopusOocytes”,Journal of General Physiology,vol. 111(1), pp. 127-138, 1998.
Delaria, K.A., et al., “Characterization of Placental Bikunin, a Novel Human Serine Protease Inhibitor”,Journal of Biological Chemistry,vol. 272(18), 12209-12214, 1997.
Dietrich, W., “Reduction of Homologous Blood Requirement in Cardiac Surgery by Intraoperative Aprotinin Application—Clinical Experience in 152 Cardiac Surgical Patients”,Thorac. Cardiovasc. Surg.,vol. 37, pp. 92-98, 1989.
Gribben, J.G. et al., “Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF”,The Lancet,vol. 335, pp. 434-437, 1990.
Hiller, L. et al., EMBL/Genbank accession No. R35464, “The WashU-Merck EST Project”, 1995.
Hiller, L. et al., EMBL/Genback accession No. R74593, “The WashU-Merck EST Project”, 1995.
Hillier, L. et al., EMBL/Genbank accession No. N39798, “The WashU-Merck EST Project”, 1996.
Hochstrasser et al., “Kunitz-Type Proteinase Inhibitors Derived by Limited Proteolysis of the Inter-β-Trypsin Inhibitor”,Hoppe-Seyler's Z. Physiol. Chem.,vol. 362, pp. 1357-1362, 1981.
Hotchkiss et al., “The Influence of Carbohydrate Structure on the Clearance of Recombinant Tissue-Type Plasminogen Activator”,Thrombosis and Harmostatis,60,(2), pp. 255-261, (1988).
Kawaguchi, T. et al, “Purification and Cloning of Hepatocyte Growth Factor Activator Inhibitor Type 2, a Kunitz-type Serine Protease Inhibitor”,J. Biol. Chem.,vol. 272, pp. 27558-27564, 1997.
Kawaguchi, T. et al., Genbank accession No. AB006534, “Homo sapiensmRNA for hepatocyte growth factor activator inhibitor type 2, complete cds”, 1998.
Lindberg, S. and Olsson H., “Tissue Kallikrein Stimulates Mucociliary Activity in the Rabbit Maxillary Sinus”,Acta Oto-Laryngologica,vol. 111(6), pp. 1126-1132, 1991.
Marlor, C. W. et al., “Identification and Cloning of Human Placental Bikunin, a Novel Serine Protease Inhibitor Containing Two Kunitz Domains”,J. of Biol. Chem.,vol. 272(18), 12202-12208, 1997.
Mathews, L.W. et al., “Studies on Pulmonary Secretions”,American Review of Respiratory Disease,vol. 88, pp. 199-204, 1963.
McAulay, A.E. et al, “Effect of UTP on ion transport in tertiary cultures of human bronchial epithelial (HBE) cells”,Pediatric Pulmonology,S 17, Abs 141, 1998.
Miyazawa, K. et al, “Activation of Hepatocyte Growth Factor in the Injured Tissues Is Mediated by Hepatocyte Growth Factor Activator”,J. Biol. Chem.,vol. 271 (7), pp. 3615-3618. 1996.
Newton, B.B. and Hall, R.L., “Mucociliary Clearance in the Guinea Pig is Increased by Ouabain (i.v.) and by Hypertonic Saline (14.4%) Aerosol”, Ed. Baum, G.L., Priel A., Roth, Y., Liron, N., Ostfeld, E.,Marcel Dekker, Inc.,pp. 285-294, 1998.
Newton, B.B. and Hall, R.L., “Inhalation of Amiloride Increases Tracheal Mucus Velocity and Decreases Tracheal Potential Difference in the Guinea Pig”,Pediatric Pulmonary,S17, Abs. 364, 1998.
O'Riordan, T. G. et al., “Elastase Contributes to Antigen-induced Mucociliary Dysfunction in Ovine Airways”,American Journal of Respiratory & Critical Care Medicine,vol. 97(5), pp. 1522-1528, 1997.
O'Riordan, T.G. et al.,“Budesonide affects allergic mucociliary dysfunction”,Journal of Applied Physiology,vol. 85(3), pp. 1086-1091, 1998.
Petersen et al., Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor:,Eur. J. Biochem,vol. 235, pp. 310-316, 1996.
Potter, J.L. et al., “Studies on Pulmonary Secretions. II. Osmolality and the Ionic Environment of Pulmonary Secretions from Patients with Cystic Fibrosis, Bronchiectasis, and Laryngectomy”,American Review of Respiratory Disease,vol. 67(1), pp. 83-87, 1967.
Rasche, B. et al., “The effect of the protease inhibitor aprotinin on lung function and on the inhibitory activity of the sputum patients with chronic obstructive bronchitis”,Arzneim.-Forsch.(Drug Res.) vol. 25(1) 110-116, 1975.
Robinson, M. et al., “Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis”,Thorax,vol. 52(10) pp. 900-903, 1997.
Schmidt, O.P., “Drug Treatment of Disturbances of Bronchial Secretion”,Med. Klin.,vol. 72(5), pp. 145-160, 1977.
Shimomura, T. et al., “Hepatocyte Growth Factor Activator Inhibitor, a Novel Kunitz-type Serine Protease Inhibitor”,J. Biol. Chem.,vol. 272, pp. 6370-6376, 1997.
Tomkiewicz, R.P. et al., “Amiloride Inhalation Therapy
Davis Gary
Delaria Katherine A.
Marlor Christopher W.
Muller Daniel K.
Tamburini Paul P.
Aerovance, Inc.
Bragdon Kathleen Kerr
DLA Piper (US)
Liu Samuel W.
LandOfFree
Human bikunin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human bikunin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human bikunin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4032185